Targeted Second-Line Treatment
نویسندگان
چکیده
منابع مشابه
Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review
It is unclear whether targeted agents can produce survival advantage in patients with advanced HCC previously treated with sorafenib. We performed this meta-analysis of randomized trials and reviewed clinical outcomes of molecular targeted agents in the second-line treatment for advanced HCC. A systematic computerized search of the electronic databases PubMed, Embase, Google Scholar, and Cochra...
متن کاملFirst-line treatment result influence second-line regimen selection in targeted therapy for metastatic renal cell carcinoma.
BACKGROUND Sequential treatments using various targeted-therapies have been recommended for metastatic renal cell carcinoma. However, regimen selection remains difficult when adapting to various clinical situations. PATIENTS AND METHODS From 2006 to 2012, 29 patients who received sequential targeted-therapy at our hospital were included for analysis of the treatment regimens and outcome. RE...
متن کاملSecond-line treatment of ovarian cancer.
Patients with epithelial ovarian cancer are often diagnosed with advanced-stage disease. Although clinical complete remissions are obtained in the majority of patients through a combination of cytoreductive surgery and chemotherapy, relapse is common. A number of agents with diverse biologic mechanisms have been identified with activity in the setting of recurrent disease. Strategies for manage...
متن کاملOptions for Second-Line Treatment in Metastatic Colorectal Cancer.
Colorectal cancer (CRC) remains a major public health problem in the United States and worldwide. The majority of patients who have CRC eventually present with metastatic disease. The overall therapeutic goals for most patients with metastatic CRC (mCRC) are to control the disease, prolong life span, and maximize quality of life. Therefore, the ratio of efficacy to toxicity is one of the most i...
متن کاملDoes a reasonable treatment approach beyond second-line exist?
In the 1990s, the outlook for a metastatic renal-cell carcinoma (mRCC) patient was particularly bleak, as the disease was resistant to conventional chemotherapy and only small subsets of patients responded to immunotherapy. This outlook improved in 2005 with the introduction of sorafenib, the first targeted therapy; it was followed by the development of other tyrosine kinase inhibitors (TKIs): ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Deutsches Aerzteblatt Online
سال: 2010
ISSN: 1866-0452
DOI: 10.3238/arztebl.2010.0492a